Blair William & Co. IL Reduces Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Blair William & Co. IL decreased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 27.8% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,127 shares of the biotechnology company’s stock after selling 435 shares during the quarter. Blair William & Co. IL’s holdings in United Therapeutics were worth $359,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. LSV Asset Management boosted its holdings in shares of United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares during the period. Swedbank AB purchased a new position in shares of United Therapeutics in the 1st quarter worth approximately $97,316,000. Nordea Investment Management AB lifted its stake in shares of United Therapeutics by 677.6% during the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after acquiring an additional 262,222 shares during the last quarter. Avidity Partners Management LP bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $52,158,000. Finally, Canada Pension Plan Investment Board lifted its stake in shares of United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after acquiring an additional 153,700 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 7,796 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84. Following the completion of the transaction, the chief financial officer now directly owns 4,264 shares of the company’s stock, valued at approximately $1,509,626.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $320.45, for a total transaction of $1,153,620.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $41,658.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 7,796 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84. Following the transaction, the chief financial officer now owns 4,264 shares in the company, valued at $1,509,626.56. The disclosure for this sale can be found here. In the last three months, insiders sold 111,252 shares of company stock valued at $36,939,427. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Trading Down 0.5 %

UTHR opened at $357.72 on Friday. The firm has a market cap of $15.91 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 1.29 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The stock has a fifty day moving average price of $341.49 and a 200-day moving average price of $294.59.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company’s revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm posted $5.24 earnings per share. As a group, equities research analysts anticipate that United Therapeutics Co. will post 24.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. TD Cowen raised their price target on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $310.00 to $321.00 in a research note on Thursday, July 11th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. Oppenheimer raised their price target on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Finally, LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.